Financials data is unavailable for this security.
View more
Year on year Amplia Therapeutics Ltd grew revenues 286.42% from 1.15m to 4.44m while net income improved from a loss of 6.24m to a smaller loss of 4.50m.
| Gross margin | -- |
|---|---|
| Net profit margin | -101.48% |
| Operating margin | -103.32% |
| Return on assets | -26.86% |
|---|---|
| Return on equity | -33.05% |
| Return on investment | -32.90% |
More ▼
Cash flow in AUDView more
In 2024, cash reserves at Amplia Therapeutics Ltd fell by 5.87m. Cash Flow from Investing was negative at 2.23k, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 5.13m for operations while cash used for financing totalled 772.98k.
| Cash flow per share | -0.0221 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.0572 |
|---|---|
| Tangible book value per share | 0.0174 |
More ▼
Balance sheet in AUDView more
| Current ratio | 1.98 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.139 |
|---|---|
| Total debt/total capital | 0.122 |
More ▼
